Abstract
Background: In Dec. 2019, a new virus (Coronavirus) was discovered in Wuhan city (China), indicating its potential for rapid fatal outbreaks in confined and cross borders areas. Statistics showed the fatality rate as about 1.4 %. Till now, there is no successful therapy for SARS-CoV-2.
 Method: The miRNAs from genome (Coronavirus/SARS-CoV-2) were analyzed using various computational approaches in this study. The complete genome sequence was retrieved from NCBI. 
 Results: We investigated potential antiviral treatment for the SARS-CoV-2 virus using host miRNAs, which could slow down the expression of viral genes to suppress viral replication. The result of our study highlighted that hsa-miR-3675-3p (MD19), hsa-miR-363-5p (MD220), hsa-miR-325 (MD306), hsa-miR-2114-5p (MD306), hsa-miR-744-3p (MR186) and hsa-miR-448 (MR186), can be used as anti-viral treatment to quell the replication of SARS-CoV-2 virus in human.
 Conclusion: The findings and observations of our study opened new possibilities to explore both the pathogenesis function of miRNA and in the development of novel antiviral drugs.
Highlights
In December 2019, a new coronavirus (SARS-CoV-2) emerged in Wuhan (China) and rapidly spread to many other countries [1,2,3]
The complete SARS-CoV-2 genome sequence was obtained from the National Center for Biotechnology Information (NCBI) (Isolate: Wuhan-Hu-1, NCBI Reference Sequence: NC_045512.2) and used for miRNA prediction
We identified miRNAs for SARS-CoV-2 in human beings using computational tools
Summary
In December 2019, a new coronavirus (SARS-CoV-2) emerged in Wuhan (China) and rapidly spread to many other countries [1,2,3]. The World Health Organization (WHO) Emergency Committee declared a global health emergency on Jan. 30, 2020, based on growing case rates. As of 24 April 2020, 177,108,695 individuals were infected by SARS-CoV-2 worldwide and 3,840,223 people died because of it. As of 19 June 2021, a total of 2,412,226,768 vaccine doses have been administered, worldwide [4]. SARS-CoV-2 is listed as a top category pathogen by several organizations including WHO, CDC and NIH because its fatality rate is up to 1.4%. Clinical signs of SARS-CoV-2 closely resemble those seen in MERS and SARS infections [8, 9]. A recent report [10] indicated that the potential source(s) has not been identified yet which caused the transmission of the virus to human beings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
